ArticleNature2018
A multi-cohort study of the immune factors associated with M. tuberculosis infection outcomes.
Erratum issuedAbstract read
In one paragraph
Article in Nature, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 150 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
150citing papers in PubMed, 2 pooled it
19.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
150 citing papers in PubMed, 2 syntheses or guidelines pooled it, 245 citations in OpenAlex.
- The immunoregulatory landscape of human tuberculosis granulomas.Nature immunology · 2022Pooled it
- Multisystem inflammatory syndrome in children: a microcosm of challenges and opportunities for translational bioinformatics in pediatric research.Current opinion in pediatrics · 2021Pooled it
- Multidimensional analyses reveal modulation of adaptive and innate immune subsets by tuberculosis vaccines.Communications biology · 2020Trial
- An Fc Receptor and IgA Functional Signature Identifies TB Disease in Children Living With HIV.Journal of the Pediatric Infectious Diseases Society · 2026Article
- Host-pathogen interactions in tuberculosis: from immunological mechanisms to translational applications.Cell insight · 2026Review
- Airway immune signatures of protection and disease progression in recent human tuberculosis household contacts.Nature immunology · 2026Article
- Th2 bias and T-cell exhaustion characterize the immunopathology of non-tuberculous mycobacterial pulmonary disease.NPJ systems biology and applications · 2026Article
- The host immune response to Mycobacterium tuberculosis determining protection or disease progression.Nature immunology · 2026Review
- IFN-γ- GranzymeB + Natural killer cells are induced by IV BCG vaccination and associated with protection against tuberculosis in rhesus macaques.Mucosal immunology · 2026Article
- The Outcome of Tuberculosis Treatment in the Presence of SARS-CoV-2 Anti-RBD Antibody.Infection and drug resistance · 2026Article
- Distribution of granzyme-expressing NK cells in tuberculosis reflects subset and compartment-specific remodeling.Frontiers in immunology · 2026Article
- Peripheral blood B-cell compartment dysregulation in multidrug-resistant tuberculosis is associated with reduced circulating marginal zone-like B cells.Frontiers in immunology · 2026Article
- B cells and iBALT in TB immunity & pathogenesis.Frontiers in immunology · 2026Review
- Research progress on the role and dysregulation of NK cells in anti-tuberculosis immunity.Frontiers in immunology · 2026Review
- ESAT-6 and CFP-10 reactive IgG in patients with tuberculosis inhibits intracellular bacteria.Cell reports · 2025Article
- Alterations in the Immune Response in Individuals with Latent Tuberculosis Infection.Pathogens (Basel, Switzerland) · 2025Review
- Type I IFN drives neutrophil swarming, impeding lung T cell-macrophage interactions and TB control.The Journal of experimental medicine · 2025Article
- Deep immune profiling delineates hallmarks of disease heterogeneity in extrapulmonary tuberculosis.Nature communications · 2025Article
- Peripheral blood cellular dynamics during the progression of human tuberculosis.Scientific reports · 2025Article
- Characterization of QuantiFERON-TB-Plus Results in Patients with Tuberculosis Infection and Multiple Sclerosis.Neurology international · 2025Article
90 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
18 authors at 9 institutions in 4 countries.
Roshni Roy ChowdhuryDepartment of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA.
Francesco VallaniaInstitute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA, USA.
Qianting YangShenzhen Key Laboratory of Infection and Immunity, Shenzhen Third People's Hospital, Shenzhen, China.
Cesar Joel Lopez AngelDepartment of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA.
Fatoumatta DarboeSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Adam Penn-NicholsonSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Virginie RozotSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Elisa NemesSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Stephanus T MalherbeDepartment of Science and Technology, National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, Stellenbosch University, Stellenbosch, South Africa.
Katharina RonacherDepartment of Science and Technology, National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, Stellenbosch University, Stellenbosch, South Africa.
Gerhard WalzlDepartment of Science and Technology, National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, Stellenbosch University, Stellenbosch, South Africa.
Willem HanekomSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Mark M DavisDepartment of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA.
Jill WinterCatalysis Foundation for Health, Emeryville, CA, USA.
Xinchun ChenDepartment of Pathogen Biology, Shenzhen University School of Medicine, Shenzhen, China.
Thomas J ScribaSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Purvesh KhatriProgram in Immunology, Stanford University School of Medicine, Stanford, CA, USA. pkhatri@stanford.edu.
Yueh-Hsiu ChienDepartment of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA. chien@stanford.edu.
Stanford University · USSouth African Tuberculosis Vaccine Initiative · ZAUniversity of Cape Town · ZACatalysis Foundation for Health · USNational Research Foundation · ZAShenzhen Third People’s Hospital · CNShenzhen University · CNStellenbosch University · ZAUniversity of Queensland · AU
Funding
Using a tonsil organoid system to probe conditions for the induction of protective antibody and T cell responses to influenza.U19AI057229 · NIAID · STANFORD UNIVERSITY · PI Mark Morris Davis · 2003 to 2026
$88.5MTranslational Incubator CoreU19AI109662 · NIAID · STANFORD UNIVERSITY · PI GLENN, JEFFREY S · 2014 to 2019
$28.6MMOLECULAR &CELLULAR IMMUNOBIOLOGYT32AI007290 · NIAID · STANFORD UNIVERSITY · PI Sean Curtis Bendall, Olivia M Martinez · 1985 to 2026
$27.0MGiant MagnetoResistive (GMR) Sensors for Measuring Influenza VaccineR01AI125197 · NIAID · STANFORD UNIVERSITY · PI UTZ, PAUL JOSEPH, WANG, SHAN X. · 2016 to 2021
$5.0MStanford Career Development Program in Omics of Lung DiseasesK12HL120001 · NHLBI · STANFORD UNIVERSITY · PI NICOLLS, MARK ROBERT, RABINOVITCH, MARLENE · 2013 to 2017
$1.3MMultidimensional Analysis of Immune Status of Latent M. Tuberculosis InfectionR21AI127128 · NIAID · STANFORD UNIVERSITY · PI CHIEN, YUEH-HSIU · 2016 to 2017
$435kNHLBI NIH HHS K12 HL120001NIAID NIH HHS R01 AI125197NIAID NIH HHS R21 AI127128NIAID NIH HHS T32 AI007290NIAID NIH HHS U19 AI057229NIAID NIH HHS U19 AI109662NIH HHS 5T32AI07290-31NIH HHS AI057229NIH HHS AI109662NIH HHS AI125197NIH HHS K12 5K12HL120001
Abstract
Most infections with Mycobacterium tuberculosis (Mtb) manifest as a clinically asymptomatic, contained state, known as latent tuberculosis infection, that affects approximately one-quarter of the global population
Indexed as
Disease ProgressionAdolescentChinaGPI-Linked ProteinsHumansInternationalityKiller Cells, NaturalLatent TuberculosisLongitudinal StudiesLymphocytesPneumoniaReceptors, IgGSouth AfricaTranscriptomeTreatment OutcomeTuberculosisFCGR3B protein, humanGPI-Linked ProteinsReceptors, IgG
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.